Canine Oral Papillomavirus (COPV) induces warts on the oral mucosa in domestic dogs and other canids. The canine oral papillomatosis (COP) is a well established animal model of mucosal papillomatosis. While the regression of a current infection is mediated by cellular immunity, humoral immunity does prevent reinfection. Question of the present study was, if unspecific stimulation of the immune system with the inducer of paramunity Baypamune® during the period of growth would have an influence on the course of canine oral papillomatosis. Clinical criteria for this purpose were period of growth, period of regression and the size and morphology of Papillomas at the end of growth. Additionally ALAT and ASAT were quantified in order to rule out deterioration of liver cells. PCV and leucocytes where monitored and a differentiation was performed. In a second part of the study, L1-antibodies and IFNg, TNF-a as well as IL-18 were determined by the Institute of Virology of the Faculty of Veterinary Medicine of the University of Leipzig. At the end of the study, biopsies of mucosa were taken for detection of viral genome. In a pre-study, three Labrador Retrievers at 14 weeks of age were challenged with 15 μl of virus suspension (40 μg of COPV-L1 Protein/ml) per site by scarification of oral mucosa. Papillomas developed at all challenged sites. These were removed during the period of growth and handed over to the Institute of Virology of the Faculty of Summary 70 Veterinary Medicine of the University of Leipzig for preparation of the suspension used in the main study. In the main study, 13 Labrador Retrievers at 14 weeks of age were challenged with 10 μl of virus suspension (40 μg of COPV-L1 Protein/ml) per site by scarification of three areas of the left oral mucosa. All animals developed at least at one site warts, totally 88 % of the challenged sites showed papillomas. 44 Days after infection, 12 dogs were divided into two groups which did not differ in time of incubation and size of the papillomas. Over a period of four weeks, one group received a total of five dosis of Baypamune®, the other group five dosis of placebo. There was no statistically significant difference between the groups regarding the period of growth, period of regression, size and morphology of the papillomas. The administration of Baypamune® during the period of growth had no effect on the clinical course of COP in this trial. However, time of application of the substances should be considered critically, since papillomas of five animals had been in regression before the first application of Baypamune® and placebo had taken place. No deterioration of liver cells could be ascertained. There was no difference between the groups regarding packed cell volume, white blood count and differentiation throughout the study. Parameters of unspecific immunity determined by the Institute of Virology, IFN-γ, TNF-a und IL-18, delivered no evaluable results. However, four animals of the placebogroup showed Papilloma-DNA in the Biopsies taken, but none of the animals, that received Baypamune®, being this a possible indicator for stimulation of cellular immunity. Anti-L1-Antibodies rose earlier in the Baypamune®group than in the placebogroup. In conclusion therapeutic efficacy of Baypamune® in dogs with present COP could not be shown in this trial, making future investigation necessary.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa.de:bsz:15-20071112-101053-7 |
| Date | 12 November 2007 |
| Creators | März, Maren |
| Contributors | Universität Leipzig, |
| Publisher | Universitätsbibliothek Leipzig |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | deu |
| Detected Language | English |
| Type | doc-type:doctoralThesis |
| Format | application/pdf |
Page generated in 0.0029 seconds